Post Scrip: The ASPL Pharmacy Law Podcast

American Society for Pharmacy Law (ASPL)

Post-Scrip is the podcast of The American Society for Pharmacy Law. ASPL is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties. ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose: Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues; Communicating accurate legal educational information; and Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law.

  1. S4E2 - Pharmacists Aren't the Telemedicine Police with Mark Boesen, PharmD, JD

    SEP 13

    S4E2 - Pharmacists Aren't the Telemedicine Police with Mark Boesen, PharmD, JD

    In this episode of Post-Script, Henry introduces Mark Boesen, PharmD, JD, founding partner of Boesen and Snow law firm. They discuss Mark's upcoming presentation "Pharmacists Aren't Telemedicine Police, But You Will Be Treated Like You Are." This presentation will address the growing regulatory scrutiny facing pharmacies dispensing telemedicine prescriptions, as state regulators, medical boards, and the DEA increasingly target pharmacies instead of directly addressing prescriber compliance concerns. Mark shares his unique 30-year journey from pharmacy practice to working for Senator John McCain, building specialty pharmacy operations at what would become Avella, and eventually founding his law firm. He discusses how his extensive pharmacy experience provides practical operational insights alongside legal expertise for his clients. The conversation explores how telemedicine prescriptions are receiving the same scrutiny as controlled substance prescriptions, creating double jeopardy when the two overlap. Mark explains his approach of providing attendees with practical resources including sample policies, procedures, and documentation strategies developed from his extensive regulatory encounters. He discusses his firm's evolution from traditional regulatory compliance work to federal litigation, particularly around compounding, telemedicine, and GLP-1 drug issues. Mark also touches on his background in substance abuse treatment and prevention from his time as Executive Director of the Maine Association of Substance Abuse Programs, highlighting the unique drug trafficking challenges Maine faces due to its extensive coastline and fishing industry. Join us at the annual conference: Developments in Pharmacy Law Seminar, November 6-9, 2025 at the Westin on the beach in Fort Lauderdale, Florida.

    15 min
  2. S4E1 - Rethinking Medications with Dr. Jerry Avorn, MD

    AUG 25

    S4E1 - Rethinking Medications with Dr. Jerry Avorn, MD

    In this special edition premiere of Post Scrip, host Henry sits down with Dr. Jerry Avorn, MD, Harvard Medical School professor and author of the groundbreaking book Rethinking Medications: Truth, Power and the Drugs You Take. Dr. Avorn, a senior internist at Mass General Brigham and author of over 600 papers, takes us on a dive into the complex world of drug approval, pricing, and pharmaceutical policy. This episode explores how the FDA's accelerated approval pathway, originally designed for AIDS drugs, has been used in part for medications like Aduhelm, the Alzheimer's drug that didn't work, could cause brain damage, and all at a high price. The conversation delves into the erosion of randomized controlled trials, the problematic influence of user fees on FDA decision-making, and Dr. Avorn's experience as an expert witness in the landmark Vioxx litigation. Dr. Avorn discusses the challenge of "doing your own research" when drug companies control access to study data, his work in academic detailing to compete with pharmaceutical marketing, and the "because I can" pricing strategy that drives up drug costs. He also shares insights about maintaining independence by refusing personal consulting fees from pharmaceutical companies and about his organizations that focus on unbiased drug evaluation and education. This conversation will hopefully encourage discussion among pharmacists, attorneys, healthcare professionals, and anyone seeking to understand the forces shaping modern medicine, drug policy, and drug pricing.

    55 min
  3. S3E10 - Regulatory, Industry and Legal Perspectives on the Future of the DSCSA | Post-Scrip: The ASPL Pharmacy Law Podcast

    10/16/2024

    S3E10 - Regulatory, Industry and Legal Perspectives on the Future of the DSCSA | Post-Scrip: The ASPL Pharmacy Law Podcast

    In this episode of Post-Scrip, Henry introduces Jenni Wai, RPh. , MBA, Josh Bolin and Christopher R. Smith, JD, LLM. They discuss the upcoming "Regulatory, Industry and Legal Perspectives on the Future of the DSCSA". This presentation will provide an update on the final stages of implementation of the DSCSA and anticipated future regulatory efforts. We will begin with a brief high level overview of the DSCSA, including a summary of recent regulatory developments, such as any new regulations or guidance documents issued by the FDA in 2024 with regard to the DSCSA. We will then pivot to address the end of the one-year FDA stabilization period, recent feedback from the pharmacy industry regarding DSCSA compliance concerns, and the readiness of the pharmacy industry to fully implement and obstacles to implementation of the interoperable electronic exchange of transaction data.  We plan to include a discussion of the tools available to pharmacies to assist with compliance with DSCSA requirements as DSCSA implementation evolves. We will further discuss the challenges that state regulators face with regard to ensuring that dispensers, wholesalers and manufacturers comply with the DSCSA, particularly with regard to ensuring that stakeholders have robust processes for identifying, investigating and responding to suspect and illegitimate products. Join us at the 35th annual conference:  Developments in Pharmacy Law Seminar , November 7-10, 2024 in Phoenix, Arizona

    15 min

Ratings & Reviews

5
out of 5
2 Ratings

About

Post-Scrip is the podcast of The American Society for Pharmacy Law. ASPL is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties. ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose: Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues; Communicating accurate legal educational information; and Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law.